Investigational drug · Phase 2
Anvumetostat
Also called: AMG 193
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced MTAP-null Solid Tumors, MTAP-deleted NSCLC, MTAP-null Non-Small-Cell Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "Anvumetostat"
First trial start
2022
Feb 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Anvumetostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced MTAP-null Solid Tumors
- MTAP-deleted NSCLC
- MTAP-null Non-Small-Cell Lung Cancer
- MTAP-null Solid Tumors
Approved drugs for the same conditions: Non-small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Anvumetostat" as an intervention, largest first.
- A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruiting
AmgenAmgen (AMGN)
NCT05094336 · 329 participants · Start Feb 1, 2022 · Primary completion Nov 30, 2026
Drug: Anvumetostat; Docetaxel and 1 more · For: Advanced MTAP-null Solid Tumors
Sites: Duarte, California; Glendale, California; Oxnard, California · 75 sites in all
AmgenAmgen (AMGN)
NCT06360354 · 120 participants · Start May 29, 2024 · Primary completion Oct 31, 2026
Drug: Anvumetostat; Gemcitabine and 3 more · For: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Sites: Bakersfield, California; Duarte, California; La Jolla, California · 77 sites in all
- A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Active, not recruiting
AmgenAmgen (AMGN)
NCT06593522 · 61 participants · Start Dec 26, 2024 · Primary completion Oct 31, 2026
Drug: anvumetostat · For: MTAP-deleted NSCLC
Sites: Duarte, California; Los Angeles, California; Denver, Colorado · 91 sites in all
AmgenAmgen (AMGN)
NCT05975073 · 53 participants · Start Aug 1, 2023 · Primary completion Feb 25, 2026
Drug: Anvumetostat; IDE397 · For: MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors
Sites: Duarte, California; Denver, Colorado; Indianapolis, Indiana · 27 sites in all
- Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active, not recruiting
AmgenAmgen (AMGN)
NCT06333951 · 49 participants · Start Sep 17, 2024 · Primary completion Oct 31, 2026
Drug: Anvumetostat; Carboplatin and 4 more · For: Thoracic Tumors; Non-small Cell Lung Cancer
Sites: Bakersfield, California; Duarte, California; Los Angeles, California · 83 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.
Rodon J, Johnson ML, George B, et al. · Cancer Res 2026
- Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.
Pettus LH, Bourbeau M, Tamayo NA, et al. · J Med Chem 2025
- AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers.
Belmontes B, Slemmons KK, Su C, et al. · Cancer Discov 2025
- First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.
Rodon J, Prenen H, Sacher A, et al. · Ann Oncol 2024
- AMG 193 Effective in Multiple Tumor Types.
· Cancer Discov 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.